

## Supporting Information for

# Metal-Directed Hierarchical Superhelices from Hybrid Peptide Foldamers

Sanjit Dey, Souvik Roy, DRGKoppalu R. Puneeth Kumar, Sachin A. Nalawade,  
Manjeet Singh, Sandip U. Toraskar, Souvik Panda Mahapatra, and Hosahudya N.  
Gopi\*


Department of Chemistry, Indian Institute of Science Education and Research  
(IISER), Pune-411008, India. E-mail: [hn.gopi@iiserpune.ac.in](mailto:hn.gopi@iiserpune.ac.in)

## Contents


[1]. ORTEP Diagrams .....	3
[2]. Crystal Structure Information .....	5
[3]. Torsion Angles and H-bond Parameters .....	6
[4]. Experimental Details .....	7
1) Experimental details of Circular Dichroism (CD) spectroscopy .....	7
2) Experimental details of FTIR spectroscopy .....	7
3) Experimental details of 2D NMR spectroscopy .....	7
4) Experimental details of AFM and TEM analysis.....	7
[5]. Metal-Peptide Complexation of P1 with CdI <sub>2</sub> .....	8
[6]. Peptide(P1)-CdI <sub>2</sub> Crystal and Dimer Formation.....	9
[7]. Peptide (P1)-CdI <sub>2</sub> Coordination Polymer to Superhelix Formation: .....	10
[8]. Packing of CdI <sub>2</sub> -Coordinated Superhelix of Peptide (P1) .....	12
[9]. Circular Dichroism (CD) Study of Metal-Peptide (P1-CdI <sub>2</sub> )Superhelix .....	13
[10]. Metal-Peptide Complexation of P2 with CdI <sub>2</sub> .....	14
[11]. Supramolecular Assembly of P2-CdI <sub>2</sub> Complex.....	15
[12] Circular Dichroism (CD) Study of Metal-Peptide (P2-CdI <sub>2</sub> ) Superhelix.....	17
[13]. Solution State Conformational Analysis (2D-NMR) of Peptide (P1) and Metal-Peptide Complexes (P1-CdI <sub>2</sub> and P2-CdI <sub>2</sub> ) .....	18
[14]. PXRD of P2-CdI <sub>2</sub> complex.....	25
[15]. Structural correlation of P1-CdI <sub>2</sub> and P2-CdI <sub>2</sub> complexes in solution and single crystals..	26
[16]. Morphology Investigation of Peptide-Metal Complexes.....	28
[17]. Comparison of Torsion Angle Parameters of Peptide and Peptide-Metal Complexes.....	29
[18]. Effect of Aib Residue and Comparison of Superhelix and Superhelical Sheet.....	30
[19]. Materials and Methods.....	31
[20]. <sup>1</sup> H, <sup>13</sup> C NMR and Mass Spectra of Peptides.....	35
[21]. References.....	42

## [1]. ORTEP Diagrams:

### A) ORTEP and Map Diagram of P1-CdI<sub>2</sub> Complex:




**Figure S1:** ORTEP diagram of **P1-CdI<sub>2</sub> complex** (CCDC = 2103330). H-bonds are shown in dotted lines. H-atoms are omitted for clarity. Ellipsoids are drawn at 50% probability.



**Map Diagram**

## B) ORTEP Diagram of P2-CdI<sub>2</sub> Complex:



**Figure S2:** ORTEP diagram of **P2-CdI<sub>2</sub> complex** (CCDC = 2172105). H-bonds are shown in dotted lines. H-atoms are omitted for clarity. Ellipsoids are drawn at 50% probability.

## [2]. Crystal Structure Information:

**A) Crystal Structure Analysis of P1-CdI<sub>2</sub> Complex:** Crystals were grown by layering 25 mM of 500  $\mu$ L solution of **P1** in methanol and 25 mM of 500  $\mu$ L of aqueous solution of CdI<sub>2</sub> in a capped microtube. A single crystal (0.20  $\times$  0.14  $\times$  0.16 mm) was mounted on a loop with a small amount of the paraffin oil. The X-ray data were collected at 100K temperature on a Bruker APEX(II) DUO CCD diffractometer using MoK $\alpha$  radiation ( $\lambda = 0.71073 \text{ \AA}$ )  $\omega$ -scans ( $2\theta = 56.898$ ), for a total of 8900 independent reflections. Space group P4<sub>1</sub>2<sub>1</sub>2,  $a = 13.826(3)$ ,  $b = 13.826(3)$ ,  $c = 37.353(12)$ ,  $\alpha, \beta, \gamma = 90$ ,  $V = 7140(4) \text{ \AA}^3$ , tetragonal,  $Z = 8$  for chemical formula C<sub>29</sub> H<sub>31</sub> Cd<sub>1</sub> I<sub>2</sub> N<sub>6</sub> O<sub>4</sub> with one molecule in asymmetric unit;  $\rho_{\text{calcd}} = 1.663 \text{ gcm}^{-3}$ ,  $\mu = 2.380 \text{ mm}^{-1}$ ,  $F(000) = 3464$ , The structure was obtained by direct methods using SHELXS-97.<sup>1</sup> The final R value was 0.0587 (wR2 = 0.1422) 5190 observed reflections ( $F_0 \geq 4\sigma(|F_0|)$ ) and 404 variables, S = 0.907

**B) Crystal Structure Analysis of P2-CdI<sub>2</sub> Complex:** Crystals were grown by complexation reaction between 25 mM of 500  $\mu$ L solution of **P2** in methanol and 25 mM of 500  $\mu$ L of CdI<sub>2</sub> in methanol. Then after 12h the clear reaction mixture left for slow evaporation. After several days later single crystal obtained. A single crystal (0.12  $\times$  0.10  $\times$  0.10 mm) was mounted on a loop with a small amount of the paraffin oil. The X-ray data were collected at 100K temperature on a Bruker APEX(II) DUO CCD diffractometer using MoK $\alpha$  radiation ( $\lambda = 0.71073 \text{ \AA}$ )  $\omega$ -scans ( $2\theta = 56.816$ ), for a total of 8997 independent reflections. Space group Pca2<sub>1</sub>,  $a = 17.103(2)$ ,  $b = 8.5730(1)$ ,  $c = 24.367(3)$ ,  $\alpha, \beta, \gamma = 90$ ,  $V = 3572.8(6) \text{ \AA}^3$ , tetragonal,  $Z = 4$  for chemical formula C<sub>29</sub> H<sub>41</sub> I<sub>2</sub> N<sub>6</sub> O<sub>4</sub> Cd<sub>1</sub> with one molecule in asymmetric unit;  $\rho_{\text{calcd}} = 1.680 \text{ gcm}^{-3}$ ,  $\mu = 2.379 \text{ mm}^{-1}$ ,  $F(000) = 1772$ . The structure was obtained by direct methods using SHELXS-97.<sup>1</sup> The final R value was 0.0488 (wR2 = 0.1069) 7269 observed reflections ( $F_0 \geq 4\sigma(|F_0|)$ ) and 385 variables, S = 1.029.

**[3]. Torsion Angles and H-bond Parameters:**

**A) Torsion Angles:**

Peptide	Residue	$\phi$	$\theta_1$	$\theta_2$	$\Psi$
<b>P1-CdI<sub>2</sub> complex</b>	Aib	52(1)	-	-	-143(1)
	$\gamma$ Leu	-123(1)	61(1)	65(1)	-115(1)
	Leu	-77(1)	-	-	-38(2)
<b>P2-CdI<sub>2</sub> complex</b>	Aib	50.5(7)	-	-	50.3(6)
	$\gamma$ Leu	129.5(6)	-60.1(7)	-62.5(7)	114.0(6)
	Leu	78.6(6)	-	-	36.4(7)

**Table S1:** Torsion angle parameters of **P1-CdI<sub>2</sub>**, and **P2-CdI<sub>2</sub>** complex.

**B) H-bond Parameters:**

Peptide	Hydrogen Bond	C=O...H-N	C=O...N-H	$\angle$ O...H-N
		in angstroms		in degrees
<b>P1-CdI<sub>2</sub> complex</b>	Py CO $\leftrightarrow$ Leu NH	2.180	3.05(1)	169.4
	Aib CO $\leftrightarrow$ NH Py	2.022	2.86(1)	158.8
<b>P2-CdI<sub>2</sub> complex</b>	Py CO $\leftrightarrow$ Leu NH	1.982(6)	2.844(6)	166.3(6)
	Aib CO $\leftrightarrow$ NH Py	2.000(6)	2.829(6)	156.4(6)

**Table S2:** H-bond parameters of **P1-CdI<sub>2</sub>**, and **P2-CdI<sub>2</sub>** complex.

#### **[4] Experimental Details:**

##### **1) Experimental details of Circular Dichroism (CD) spectroscopy:**

CD spectra of the P1-CdI<sub>2</sub> and P1-CdI<sub>2</sub> (0.5mg/mL) in MeOH were recorded using JASCO(J-815) spectrometer fitted with a Peltier temperature controller set to 25 °C, using quartz cuvettes with an optical path length of 0.1 mm. The scan was performed in steps of 1 nm over a wavelength range of 190-350 nm with a spectral bandwidth of 1.0 nm and an averaging time of 3 s. The full spectrum of the sample was collected three times and averaged. The baseline was similarly recorded for MeOH and subtracted from the sample spectra.

##### **2) Experimental details of FTIR spectroscopy:**

Solution phase FTIR spectra of P1-CdI<sub>2</sub> and P1-CdI<sub>2</sub> (1.5mg/mL) in MeOH were measured at 298 K using Fourier-Transform IR spectrometer (Bruker Alpha II).


##### **3) Experimental details of 2D NMR spectroscopies:**

NMR spectra were recorded on 600 MHz Bruker spectrometer in DMSO-d<sub>6</sub> solvent. Nearly 5mM of both peptide and metal-peptide complex concentrations were used. Temperature was maintained at 298 K to move away residual water signal away from C $\alpha$  proton signals and the water suppression power had minimal effect on nearby peptide resonances. Resonance assignments were carried by using TOCSY and ROESY spectra. All 2D spectral widths were 12 ppm with 2048 x 512-time domain points in t<sub>2</sub> S<sub>5</sub> and t<sub>1</sub> domains respectively. Data set was zero filled to 2K x 1K before Fourier transformation. A mixing time of 100ms and 250ms were used for TOCSY and ROESY spectrum respectively. All NMR data were processed offline using TOPSPIN version 2.1 software. Scalar coupling (J) values were directly measured from high resolution 1D recording.

##### **4) Experimental details of AFM and TEM Analysis:**

AFM samples were prepared by depositing metal-peptide solution (4 $\mu$ L, 1mg/mL in MeOH) drop casted on mica, dried at room temperature and imaged. Similarly, TEM on copper grid, dried at room temperature and imaged it.



[5]. Metal-Peptide Complexation of P1 with CdI<sub>2</sub>:



**Figure S3:** Metal-peptide complexation of **P1** with different metal salts. The change in the torsion angle parameters ( $\phi$  and  $\psi$ ) of **Aib** residue before and after complexation has been shown.




[6]. Peptide(P1)-CdI<sub>2</sub> Crystal and Dimer Formation:




**Head to Tail Metal Coordination**

**Figure S4:** Mode of peptide (P1)-metal coordination.

**[7]. Peptide (P1)-CdI<sub>2</sub> Coordination Polymer to Superhelix Formation:**



**Side view of superhelix**



Top view of superhelix






Figure S5: Peptide (P1)-CdI<sub>2</sub> coordinated superhelical polymer.

[8]. Packing of CdI<sub>2</sub>-Coordinated Superhelix of Peptide (P1):




**Figure S6:** Packing of CdI<sub>2</sub>-coordinated superhelix of peptide (P1).

[9]. Circular Dichroism (CD) Study of Metal-Peptide Superhelix:



**Figure S7:** Circular Dichroism study of peptide and peptide-metal salts shows a strong absorption band at  $\lambda_{\max} = 230$  nm.


[10]. Metal-Peptide Complexation of P2 with CdI<sub>2</sub> :



**Figure S8:** Metal-peptide complexation of **P2** with different metal salts. The change in the torsion angle parameters ( $\phi$  and  $\Psi$ ) of **Aib** residue before and after complexation has been shown.


[11]. Supramolecular Assembly of P2-CdI<sub>2</sub> Complex:

a)




Head to Tail Metal Coordination

b)




Metal coordinated superhelix (side view)



c)




Metal coordinated superhelix (top view)

d)






**Superhelical  $\beta$ -sheet assembly**





**Figure S9:** The X-ray diffracted structure of P2-CdI<sub>2</sub> complex. a) Cd<sup>2+</sup> ion coordination between the two helices in a “Head-to-Tail” fashion with an angle of pyridine units observed in the crystal packing. b-e) metal coordinated superhelix. f) formation of superhelical sheet assembly by intermolecular H-bond and addition Cd-I---H-C interaction with 3.01 Å. g) A cartoon representation of superhelical β-sheet assembly.



**[12] Circular Dichroism (CD) Study of Metal-Peptide (P2-CdI<sub>2</sub>) Superhelix:**




**Figure S10:** Circular Dichroism study of peptide and peptide-metal salts shows a strong absorption band at  $\lambda_{\max} = 234$  nm and at  $\lambda_{\min} = 207$  nm.

[13]. Solution State Conformational Analysis (2D-NMR) of Peptide (P1) and Metal-Peptide Complex (P1-CdI<sub>2</sub> and P2-CdI<sub>2</sub>):


A) 2D-NMR Analysis of Peptide (P1)






**Figure S11:** (a) TOCSY spectrum of peptide **P1** in DMSO- $d_6$ . Partial ROESY spectrum of **P1** (b) showing  $\text{NH} \leftrightarrow \text{NH}$  NOEs and (c) showing  $\text{C}\alpha\text{H} \leftrightarrow \text{NH}$  NOEs.



## B) 2D-NMR Analysis of Metal Peptide Complex (**P1**- $\text{CdI}_2$ )






**Figure S12:** (a) TOCSY spectrum of **P1-CdI<sub>2</sub>** complex in DMSO-*d*<sub>6</sub>. Partial ROESY spectrum of **P1-CdI<sub>2</sub>** complex (b) showing NH↔NH NOEs and (c) showing C $\alpha$ H↔NHNOEs.


### C) 2D-NMR Analysis of Metal Peptide Complex (P2-CdI<sub>2</sub>)









**Figure S13:** (a) TOCSY spectrum of **P2-CdI<sub>2</sub>** complex in DMSO-*d*<sub>6</sub>. Partial ROESY spectrum of **P2-CdI<sub>2</sub>** complex (b) showing NH↔NH NOEs and (c) showing CαH↔NHNOEs.

### D) Temperature Dependent NMR Analysis and Correlation of Coupling Constant with Torsion Angle of Metal-Peptide Complex (P2-CdI<sub>2</sub>):




**Figure S14:** Partial <sup>1</sup>H-NMR spectrum of P2-CdI<sub>2</sub> complex at different temperatures.

Temp(K)	Chemical Shift ( $\delta_{\text{ppm}}$ ) for P2-CdI <sub>2</sub> complex			
	C terminal-NH	$\alpha$ Aib-NH	$\alpha$ Leu-NH	$\gamma$ Leu-NH
298	10.20	8.62	7.85	7.53
313	10.14	8.54	7.78	7.46
328	10.07	8.46	7.73	7.39
343	9.98	8.37	7.66	7.31
358	9.91	8.29	7.60	7.24
373	9.83	8.21	7.53	7.16
$\Delta\delta/\Delta T$ (ppb K <sup>-1</sup> )	<b>-5.01</b>	<b>-5.5</b>	<b>-4.21</b>	<b>-4.93</b>




**Figure S15:** Temperature dependent <sup>1</sup>H-NMR analysis of CONH signals and  $\Delta\delta/\Delta T$  of P2-CdI<sub>2</sub> complex in DMSO-d<sub>6</sub>.






**Figure S16:** Partial  $^1\text{H}$ -NMR spectrum of  $\text{P2-CdI}_2$  complex and coupling constants.

**[14]. PXRD of  $\text{P2-CdI}_2$  complex:**




**Figure S17:** PXRD of  $\text{P2-CdI}_2$  complex

**[15]. Structural Correlation of P1-CdI<sub>2</sub> and P2-CdI<sub>2</sub> Complexes in Solution and Single Crystals:**



**Figure S18:** Partial <sup>1</sup>H-NMR spectra for the analysis of coupling constant of P1-CdI<sub>2</sub> complex in DMSO-d<sub>6</sub>.



**Figure S19:** Partial <sup>1</sup>H-NMR spectra for the analysis of coupling constant of P2-CdI<sub>2</sub> complex in DMSO-d<sub>6</sub>.

Calculation of phi angle from Coefficients of Karplus Equations,  ${}^3J_{\text{HNH}\alpha} = A \cos^2(\phi + \theta) + B \cos(\phi + \theta) + C$

[Where,  ${}^3J_{\text{HNH}\alpha} = 6.8$ ,  $\theta = -60^\circ$ ,  $A = +6.98$ ,  $B = -1.38$ , and  $C = +1.72$ ].

Metal Peptide Complex	Phi( $\phi$ ) of alpha Leu	
	NMR	XRD
P1-CdI <sub>2</sub>	76.7	-77.0
P2-CdI <sub>2</sub>	76.7	78.6

These results strongly indicate almost similar helical conformations of peptides in both solution and in single crystals.

## [16]. Morphology Investigation of Peptide-Metal Complexes:





Figure S20: AFM images of a) P1-CdI<sub>2</sub> and b) P2-CdI<sub>2</sub> complexes




**Figure S21:** TEM images of a) P1-CdI<sub>2</sub> and b) P2-CdI<sub>2</sub> complexes

**[17]. Comparison of Torsion Angle Parameters of Peptide and Peptide-Metal Complexes:**

Complex	Residue	$\phi$	$\theta_1$	$\theta_2$	$\Psi$
<b>Ligand Peptide P1</b>	<b>Aib</b>	<b>-55.4(7)</b>	<b>-</b>	<b>-</b>	<b>-39.8(7)</b>
	<b><math>\gamma</math>Leu</b>	<b>-133.3(6)</b>	<b>55.2(6)</b>	<b>60.1(6)</b>	<b>-112.6(5)</b>
	<b>Leu</b>	<b>-60.1(6)</b>	<b>-</b>	<b>-</b>	<b>-41(6)</b>
<b>P1-CdI<sub>2</sub> complex</b>	<b>Aib</b>	<b>52(1)</b>	<b>-</b>	<b>-</b>	<b>-143(1)</b>
	<b><math>\gamma</math>Leu</b>	<b>-123(1)</b>	<b>61(1)</b>	<b>65(1)</b>	<b>-115(1)</b>
	<b>Leu</b>	<b>-77(1)</b>	<b>-</b>	<b>-</b>	<b>-38(2)</b>
<b>Ligand Peptide P2</b>	<b>Aib</b>	<b>-57.1(5)</b>	<b>-</b>	<b>-</b>	<b>-44.3(5)</b>
	<b><math>\gamma</math>Leu</b>	<b>-122.0(4)</b>	<b>48.3(5)</b>	<b>69.1(5)</b>	<b>-116.8(4)</b>
	<b>Leu</b>	<b>-88.0(5)</b>	<b>-</b>	<b>-</b>	<b>-19.6(6)</b>
<b>P2-CdI<sub>2</sub> complex</b>	<b>Aib</b>	<b>50.5(7)</b>	<b>-</b>	<b>-</b>	<b>50.3(6)</b>
	<b><math>\gamma</math>Leu</b>	<b>129.5(6)</b>	<b>-60.1(7)</b>	<b>-62.5(7)</b>	<b>114.0(6)</b>
	<b>Leu</b>	<b>78.6(6)</b>	<b>-</b>	<b>-</b>	<b>36.4(7)</b>

**Table S3:** Torsion angle parameters of P1, P2 and Peptide-CdI<sub>2</sub> complexes.

**[18]. Effect of Aib Residue and Comparison of Superhelix and Superhelical Sheet:**




**Figure S22:** Effect of Aib Residue and Comparison of Superhelix and Superhelical Sheet.

### [19]. Materials and Methods:

All the amino acids, HBTU, HOAt,  $\text{CdI}_2$ , and NMR solvents, THF, DCM, DMF, methanol, ethanol, chloroform, EtOAc, 4-aminopyridine, isonicotinic acid, di-tert-butyl dicarbonate, TFA, ethyl bromoacetate, triphenyl phosphine, oxone, DIPEA,  $\text{NaBH}_4$ , DCC and HOBt were obtained from commercial sources and used without further purification. Column chromatography was performed on silica gel (120–200 mesh). The  $^1\text{H}$  NMR spectra were recorded on 400 MHz (or 100 MHz for  $^{13}\text{C}$  NMR) / spectrometer using residual solvent signals as an internal reference ( $\text{CDCl}_3$   $^1\text{H}$ -7.26 ppm,  $^{13}\text{C}$ - 77.16 ppm). The chemical shifts ( $\delta$ ) are reported in ppm and coupling constants ( $J$ ) in Hz.

### General Procedure for the Synthesis of Peptide P1:



*N*-Boc protected Leucine (10 mmol, 2.31 g) was dissolved in 10 mL of DMF and was cooled down to 0 °C under N<sub>2</sub> atmosphere. To this, HBTU (10 mmol, 3.79 g) and HOBt (10 mmol, 1.36 g) were added and the reaction mixture was stirred for 10 minutes. This was followed by the addition of 4-aminopyridine (12 mmol, 1.13 g). The reaction mixture was stirred for overnight and the progress was monitored by TLC. Upon completion, the reaction mixture was diluted with 150 mL EtOAc and was washed with water (100 mL X 2), 10% Na<sub>2</sub>CO<sub>3</sub> (100 mL X 3) and finally with brine solution (100 mL X 2). The organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to give a crude powder which was then purified by column chromatography (60% EtOAc in Hexane) to get a white crystalline product Compound 1 (Yield- 2.5 g, 82%).

Compound C1 (5.2 mmol, 1.6 g) was subjected to Boc deprotection using 50% TFA in DCM (5 mL TFA in 5 mL DCM). Upon completion, the reaction mixture was evaporated several times with DCM to remove the residual TFA. The resulting TFA salt of amine was dissolved in 2 mL DMF and was quenched with DIPEA (15 mmol, 2.7 mL) to get the free amine of compound C1.

*N*-Boc protected  $\gamma$ -leucine (5 mmol, 1.30 g) was dissolved in 3 mL of DMF and this solution was then cooled to 0 °C using an ice bath in N<sub>2</sub> atmosphere. To this, HBTU (5 mmol, 1.90 g), HOBt (5 mmol, 0.68 g), and DIPEA (10 mmol, 1.8 ml) were added and the reaction mixture was stirred for 10 mins. This was followed by the addition of amine cocktail of compound C1 and the reaction mixture was further stirred for overnight at room temperature. Upon completion, the reaction mixture was diluted with 150 mL of EtOAc and was washed with water (100 mL X 2), 10% Na<sub>2</sub>CO<sub>3</sub> solution (100 mL X 3) and finally with brine (100 mL X 2). The organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to give a crude peptide which was then purified by column chromatography (75% EtOAc in Hexane) to get pure compound C2 (Yield- 1.7 g, 73%).



Compound C2 (3.79 mmol, 1.7 g) was then subjected to Boc deprotection using 50% TFA in DCM (4 mL TFA in 4 mL DCM). Upon completion, the reaction mixture was evaporated several times with DCM to remove the residual TFA. The resulting TFA salt of the amine was dissolved in 1 mL DMF and was quenched with DIPEA (12 mmol, 2.0 mL) to get free amine of compound C2.


*N*-Boc protected 2-amino isobutyric acid (Aib) (3.7 mmol, 0.75 g) was dissolved in 3.0 mL of DMF and the solution was then cooled to 0 °C using an ice bath in N<sub>2</sub> atmosphere. To this, HBTU (3.7 mmol, 1.41 g), HOAt (3.7 mmol, 0.50 g) and DIPEA (7.4 mmol, 1.3 mL) were added and the reaction mixture was stirred for 10 mins. This was followed by the addition of amine cocktail of compound C2 and the reaction mixture was further stirred overnight at room temperature. Upon completion, the reaction mixture was diluted with 150 mL of EtOAc and was washed with water (100 mL X 2), 10% Na<sub>2</sub>CO<sub>3</sub> solution (100 mL X 3) and finally with brine solution (100 mL X 2). The organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to give a crude peptide which was then purified by column chromatography (EtOAc) to get pure compound C3 (Yield- 1.3 g, 66%).

The compound C3 (2.4 mmol, 1.3 g) was further subjected to Boc deprotection using 50% TFA in DCM (3 mL TFA in 3 mL DCM). Upon completion, the reaction mixture was evaporated several times with DCM to remove the residual TFA. The resulting TFA salt of the amine was dissolved in 1 mL DMF and was quenched with DIPEA (7.2 mmol, 1.3 mL) to get the free amine of compound C3.

Finally, 2 mL of DMF was added to isonicotinic acid (2.3 mmol, 0.283 g) and it was then cooled down to 0 °C using an ice bath in N<sub>2</sub> atmosphere. To this, HBTU (2.3 mmol, 0.87 g), HOAt (2.3 mmol, 0.32 g) and DIPEA (4.6 mmol, 0.8 mL) were added and the reaction mixture was stirred 10 mins. This was followed by the addition of amine cocktail of compound C3 and the reaction mixture was further stirred overnight at room temperature. Upon completion, the reaction


mixture was diluted with 150 mL of EtOAc and was washed with water (100 mL X 2), 10% Na<sub>2</sub>CO<sub>3</sub> solution (100 mL X 3) and finally with brine solution (100 mL X 2). The organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to give a crude peptide which was then subjected to column chromatography (10% MeOH in DCM ) to get the pure peptide, **P1** (Yield- 0.88 g, 71%).

### General Procedure for the Synthesis of Peptide **P2**:



The synthesis of **P2** was carried out as described in the above scheme, following similar protocols as of **P1** (Yield- 0.62 g, 68%).

[20].  $^1\text{H}$ ,  $^{13}\text{C}$  NMR and Mass Spectra of Peptide:




**P1**

$^1\text{H}$  NMR (400 MHz,  $\text{DMSO-}d_6$ )  $\delta$  10.42 (s, 1H), 8.75 – 8.68 (m, 2H), 8.65 (s, 1H), 8.45 – 8.37 (m, 2H), 7.88 (d,  $J = 6.7$  Hz, 1H), 7.81 – 7.74 (m, 2H), 7.71 – 7.61 (m, 2H), 7.53 (d,  $J = 9.3$  Hz, 1H), 4.23 (dt,  $J = 9.6, 6.1$  Hz, 1H), 3.77 (dt,  $J = 9.0, 4.5$  Hz, 1H), 2.28 – 2.13 (m, 1H), 2.09 (ddd,  $J = 13.7, 7.3, 5.0$  Hz, 1H), 1.77 – 1.58 (m, 3H), 1.50 (d,  $J = 8.4$  Hz, 6H), 1.45 (ddd,  $J = 11.5, 9.0, 5.6$  Hz, 1H), 1.33 (dd,  $J = 9.1, 4.5$  Hz, 1H), 1.12 (td,  $J = 8.9, 4.5$  Hz, 1H), 0.84 (d,  $J = 6.6$  Hz, 3H), 0.80 (d,  $J = 6.5$  Hz, 3H), 0.74 (dd,  $J = 6.5, 1.1$  Hz, 6H).

$^{13}\text{C}$  NMR (101 MHz,  $\text{DMSO-}d_6$ )  $\delta$  173.84, 172.99, 172.90, 164.97, 150.14, 149.90, 146.12, 141.70, 121.65, 113.68, 56.92, 53.22, 46.13, 44.02, 40.41, 31.74, 31.48, 25.32, 25.00, 24.41, 24.36, 23.14, 22.84, 22.04, 21.50.

**MALDI TOF/TOF**  $m/z$  calculated for  $\text{C}_{29}\text{H}_{42}\text{N}_6\text{O}_4$   $[\text{M}+\text{Na}]$  is 561.327 and observed value is 561.628




**P2**


**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)** δ 10.36 (s, 1H), 9.12 (d, *J* = 2.2 Hz, 1H), 8.80 (d, *J* = 2.4 Hz, 1H), 8.49 (s, 1H), 8.43 (dd, *J* = 4.7, 1.6 Hz, 1H), 8.20 (dd, *J* = 4.7, 1.5 Hz, 1H), 8.16 (dt, *J* = 8.1, 2.0 Hz, 1H), 8.05 (s, 1H), 7.93 (dt, *J* = 8.3, 2.0 Hz, 1H), 7.44 (d, *J* = 9.7 Hz, 1H), 7.07 (dd, *J* = 8.0, 4.7 Hz, 1H), 7.00 (dd, *J* = 8.4, 4.7 Hz, 1H), 4.23 (dt, *J* = 10.0, 4.7 Hz, 1H), 4.07 (d, *J* = 13.1 Hz, 1H), 2.61 (t, *J* = 12.2 Hz, 1H), 2.32 – 2.17 (m, 2H), 1.94 (dd, *J* = 13.4, 6.8 Hz, 1H), 1.84 (s, 3H), 1.71 (s, 3H), 1.66 – 1.56 (m, 3H), 1.52 – 1.35 (m, 3H), 0.90 (dd, *J* = 13.4, 6.4 Hz, 6H), 0.80 (dd, *J* = 8.9, 6.5 Hz, 6H).

**<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)** δ 175.22, 174.55, 173.46, 166.21, 152.40, 149.12, 144.51, 142.10, 135.77, 135.18, 129.02, 127.02, 122.99, 57.87, 56.36, 46.40, 41.19, 32.33, 32.03, 27.22, 25.37, 24.91, 23.97, 23.44, 23.21, 22.67, 21.73.

**MALDI TOF/TOF** m/z calculated for C<sub>29</sub>H<sub>42</sub>N<sub>6</sub>O<sub>4</sub> [M+Na] is 561.327 and the Observed value is 561.524



**Figure S23:**  $^1\text{H}$  NMR spectrum of **P1** in  $\text{DMSO-d}_6$ .



**Figure S24:**  $^{13}\text{C}$  NMR spectrum of P1 in DMSO- $d_6$ .




Figure S25:  $^1\text{H}$  NMR spectrum of P2 in  $\text{CDCl}_3$





Figure S26: <sup>13</sup>C NMR spectrum of P2 in CDCl<sub>3</sub>.



### Spectrum Report

Final - Shots 1000 - IISER-96-2-2018; Label C7



**Figure S27:** MALDI-TOF/TOF mass spectrum of **P1**.

